VolitionRx Limited (VNRX)

Market Cap	49.96M
Revenue (ttm)	1.23M
Net Income (ttm)	-26.97M
Shares Out	96.54M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,777
Open	0.5054
Previous Close	0.5195
Day's Range	0.5054 - 0.5350
52-Week Range	0.4200 - 0.9000
Beta	1.00
Analysts	Strong Buy
Price Target	3.75 (+624.64%)
Earnings Date	May 20, 2025

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived D...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cameron Reynolds
• Employees: 85
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VNRX
• Website: https://www.volition.com

Financial Performance

In 2024, VolitionRx's revenue was $1.23 million, an increase of 59.10% compared to the previous year's $775,302. Losses were -$26.97 million, -23.65% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 624.64% from the latest price.

Price Target

$3.75

(624.64% upside)

Analyst Consensus: Strong Buy